PUTRAJAYA The 393rd Drug Control Authority meeting on Friday (Feb 8) approved the registration of Zolgensma, a cell and gene therapy product, for the first time since the product's control came into force on Jan 1, 2021.
Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.
Cara Therapeutics Appoints Helen M Boudreau to Board of Directors tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.